Cytomegalovirus in Hematopoietic Stem Cell Transplant Recipients: Prevention, Diagnosis, and Treatment

Living reference work entry


Human herpesvirus 5, better known as cytomegalovirus (CMV), infects 50–90% of the adult population worldwide and is the most common opportunistic infection in allogeneic hematopoietic stem cell transplant (HSCT) recipients, causing significant morbidity and mortality [1–6]. Without prophylaxis, CMV reactivation occurs in up to 70–80% of CMV-seropositive individuals [6–9]. This chapter will review the current understanding of CMV infection in HSCT recipients focusing on emerging concepts and updated recommendations for CMV prevention, diagnosis, and management.


Cytomegalovirus Hematopoietic cell transplant Prophylaxis Pre-emptive therapy Resistance 


  1. 1.
    Boeckh M, Geballe AP. Cytomegalovirus: pathogen, paradigm, and puzzle. J Clin Invest. 2011;121(5):1673–80.CrossRefPubMedPubMedCentralGoogle Scholar
  2. 2.
    de la Camara R. CMV in hematopoietic stem cell transplantation. Mediterr J Hematol Infect Dis. 2016;8(1):e2016031.CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    Boeckh M, Ljungman P. How we treat cytomegalovirus in hematopoietic cell transplant recipients. Blood. 2009;113(23):5711–9.CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    Camargo JF, Komanduri KV. Emerging concepts in cytomegalovirus infection following hematopoietic stem cell transplantation. Hematol Oncol Stem Cell Ther. 2017;10:233–8.CrossRefGoogle Scholar
  5. 5.
    El Chaer F, Shah DP, Chemaly RF. How I treat resistant cytomegalovirus infection in hematopoietic cell transplantation recipients. Blood. 2016;128(23):2624–36.CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    Ljungman P, Hakki M, Boeckh M. Cytomegalovirus in hematopoietic stem cell transplant recipients. Hematol Oncol Clin North Am. 2011;25(1):151–69.CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    Solano C, Gimenez E, Albert E, et al. Pre-engraftment cytomegalovirus DNAemia in allogeneic hematopoietic stem cell transplant recipients: incidence, risk factors, and clinical outcomes. Bone Marrow Transplant. 2019;54(1):90–8.CrossRefGoogle Scholar
  8. 8.
    Camargo JF, Kimble E, Rosa R, et al. Impact of cytomegalovirus viral load on probability of spontaneous clearance and response to preemptive therapy in allogeneic stem cell transplantation recipients. Biol Blood Marrow Transplant. 2018;24(4):806–14.CrossRefGoogle Scholar
  9. 9.
    Green ML, Leisenring W, Xie H, et al. Cytomegalovirus viral load and mortality after haemopoietic stem cell transplantation in the era of pre-emptive therapy: a retrospective cohort study. Lancet Haematol. 2016;3(3):e119–27.CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    Minton K. Viral immunity: how CMV bypasses immune memory. Nat Rev Immunol. 2010;10(5):288.CrossRefGoogle Scholar
  11. 11.
    Bate SL, Dollard SC, Cannon MJ. Cytomegalovirus seroprevalence in the United States: the national health and nutrition examination surveys, 1988–2004. Clin Infect Dis. 2010;50(11):1439–47.CrossRefGoogle Scholar
  12. 12.
    Hyde TB, Schmid DS, Cannon MJ. Cytomegalovirus seroconversion rates and risk factors: implications for congenital CMV. Rev Med Virol. 2010;20(5):311–26.CrossRefGoogle Scholar
  13. 13.
    Ljungman P, Brandan R. Factors influencing cytomegalovirus seropositivity in stem cell transplant patients and donors. Haematologica. 2007;92(8):1139–42.CrossRefGoogle Scholar
  14. 14.
    Souza MA, Passos AM, Treitinger A, Spada C. Seroprevalence of cytomegalovirus antibodies in blood donors in southern, Brazil. Rev Soc Bras Med Trop. 2010;43(4):359–61.CrossRefGoogle Scholar
  15. 15.
    Lodding IP, da Cunha Bang C, Sorensen SS, et al. Cytomegalovirus (CMV) disease despite weekly preemptive CMV strategy for recipients of solid organ and hematopoietic stem cell transplantation. Open Forum Infect Dis. 2018;5(5):ofy080.CrossRefPubMedPubMedCentralGoogle Scholar
  16. 16.
    Styczynski J. Who is the patient at risk of CMV recurrence: a review of the current scientific evidence with a focus on hematopoietic cell transplantation. Infect Dis Ther. 2018;7(1):1–16.CrossRefGoogle Scholar
  17. 17.
    Marchesi F, Pimpinelli F, Ensoli F, Mengarelli A. Cytomegalovirus infection in hematologic malignancy settings other than the allogeneic transplant. Hematol Oncol. 2018;36(2):381–91.CrossRefGoogle Scholar
  18. 18.
    Ljungman P, de la Camara R, Cordonnier C, et al. Management of CMV, HHV-6, HHV-7 and Kaposi-sarcoma herpesvirus (HHV-8) infections in patients with hematological malignancies and after SCT. Bone Marrow Transplant. 2008;42(4):227–40.CrossRefGoogle Scholar
  19. 19.
    Nichols WG, Price TH, Gooley T, Corey L, Boeckh M. Transfusion-transmitted cytomegalovirus infection after receipt of leukoreduced blood products. Blood. 2003;101(10):4195–200.CrossRefGoogle Scholar
  20. 20.
    Huang YT, Neofytos D, Foldi J, et al. Cytomegalovirus infection after CD34(+)-selected hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2016;22(8):1480–6.CrossRefPubMedPubMedCentralGoogle Scholar
  21. 21.
    Ljungman P, Perez-Bercoff L, Jonsson J, et al. Risk factors for the development of cytomegalovirus disease after allogeneic stem cell transplantation. Haematologica. 2006;91(1):78–83.PubMedGoogle Scholar
  22. 22.
    Kalra A, Williamson T, Daly A, et al. Impact of donor and recipient cytomegalovirus serostatus on outcomes of antithymocyte globulin-conditioned hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2016;22(9):1654–63.CrossRefGoogle Scholar
  23. 23.
    Komanduri KV, St John LS, de Lima M, et al. Delayed immune reconstitution after cord blood transplantation is characterized by impaired thymopoiesis and late memory T-cell skewing. Blood. 2007;110(13):4543–51.CrossRefPubMedPubMedCentralGoogle Scholar
  24. 24.
    Melendez-Munoz R, Marchalik R, Jerussi T, et al. Cytomegalovirus infection incidence and risk factors across diverse hematopoietic cell transplantation platforms using a standardized monitoring and treatment approach: a comprehensive evaluation from a single institution. Biol Blood Marrow Transplant. 2019;25(3):577–86.CrossRefGoogle Scholar
  25. 25.
    Milano F, Pergam SA, Xie H, et al. Intensive strategy to prevent CMV disease in seropositive umbilical cord blood transplant recipients. Blood. 2011;118(20):5689–96.CrossRefPubMedPubMedCentralGoogle Scholar
  26. 26.
    Takami A, Mochizuki K, Asakura H, Yamazaki H, Okumura H, Nakao S. High incidence of cytomegalovirus reactivation in adult recipients of an unrelated cord blood transplant. Haematologica. 2005;90(9):1290–2.PubMedGoogle Scholar
  27. 27.
    Dahi PB, Perales MA, Devlin SM, et al. Incidence, nature and mortality of cytomegalovirus infection after double-unit cord blood transplant. Leuk Lymphoma. 2015;56(6):1799–805.CrossRefGoogle Scholar
  28. 28.
    Law AD, Salas MQ, Lam W, et al. Reduced-intensity conditioning and dual T Lymphocyte suppression with antithymocyte globulin and post-transplant cyclophosphamide as graft-versus-host disease prophylaxis in haploidentical hematopoietic stem cell transplants for hematological malignancies. Biol Blood Marrow Transplant. 2018;24(11):2259–64.CrossRefGoogle Scholar
  29. 29.
    Slade M, Goldsmith S, Romee R, et al. Epidemiology of infections following haploidentical peripheral blood hematopoietic cell transplantation. Transpl Infect Dis. 2017;19:e12629: 1–10.Google Scholar
  30. 30.
    Tischer J, Engel N, Fritsch S, et al. Virus infection in HLA-haploidentical hematopoietic stem cell transplantation: incidence in the context of immune recovery in two different transplantation settings. Ann Hematol. 2015;94(10):1677–88.CrossRefGoogle Scholar
  31. 31.
    Torres HA, Kontoyiannis DP, Aguilera EA, et al. Cytomegalovirus infection in patients with lymphoma: an important cause of morbidity and mortality. Clin Lymphoma Myeloma. 2006;6(5):393–8.CrossRefGoogle Scholar
  32. 32.
    Prestes DP, Arbona E, Nevett-Fernandez A, et al. Dasatinib use and risk of cytomegalovirus reactivation after allogeneic hematopoietic-cell transplantation. Clin Infect Dis. 2017;65(3):510–3.CrossRefGoogle Scholar
  33. 33.
    von Hofsten J, Johnsson Forsberg M, Zetterberg M. Cytomegalovirus retinitis in a patient who received ruxolitinib. N Engl J Med. 2016;374(3):296–7.CrossRefGoogle Scholar
  34. 34.
    Kroger N, Shahnaz Syed Abd Kadir S, Zabelina T, et al. Peritransplantation ruxolitinib prevents acute graft-versus-host disease in patients with myelofibrosis undergoing allogenic stem cell transplantation. Biol Blood Marrow Transplant. 2018;24(10):2152–6.CrossRefGoogle Scholar
  35. 35.
    Ozdemir E, Saliba RM, Champlin RE, et al. Risk factors associated with late cytomegalovirus reactivation after allogeneic stem cell transplantation for hematological malignancies. Bone Marrow Transplant. 2007;40(2):125–36.CrossRefGoogle Scholar
  36. 36.
    Marty FM, Ljungman P, Chemaly RF, et al. Letermovir prophylaxis for cytomegalovirus in hematopoietic-cell transplantation. N Engl J Med. 2017;377(25):2433–44.CrossRefGoogle Scholar
  37. 37.
    Boeckh M, Leisenring W, Riddell SR, et al. Late cytomegalovirus disease and mortality in recipients of allogeneic hematopoietic stem cell transplants: importance of viral load and T-cell immunity. Blood. 2003;101(2):407–14.CrossRefGoogle Scholar
  38. 38.
    Reusser P, Riddell SR, Meyers JD, Greenberg PD. Cytotoxic T-lymphocyte response to cytomegalovirus after human allogeneic bone marrow transplantation: pattern of recovery and correlation with cytomegalovirus infection and disease. Blood. 1991;78(5):1373–80.CrossRefGoogle Scholar
  39. 39.
    Ozdemir E, St John LS, Gillespie G, et al. Cytomegalovirus reactivation following allogeneic stem cell transplantation is associated with the presence of dysfunctional antigen-specific CD8+ T cells. Blood. 2002;100(10):3690–7.CrossRefGoogle Scholar
  40. 40.
    Krol L, Stuchly J, Hubacek P, et al. Signature profiles of CMV-specific T-cells in patients with CMV reactivation after hematopoietic SCT. Bone Marrow Transplant. 2011;46(8):1089–98.CrossRefGoogle Scholar
  41. 41.
    Nesher L, Shah DP, Ariza-Heredia EJ, et al. Utility of the enzyme-linked immunospot interferon-gamma-release assay to predict the risk of cytomegalovirus infection in hematopoietic cell transplant recipients. J Infect Dis. 2016;213(11):1701–7.CrossRefPubMedPubMedCentralGoogle Scholar
  42. 42.
    Tey SK, Kennedy GA, Cromer D, et al. Clinical assessment of anti-viral CD8+ T cell immune monitoring using QuantiFERON-CMV(R) assay to identify high risk allogeneic hematopoietic stem cell transplant patients with CMV infection complications. PLoS One. 2013;8(10):e74744.CrossRefPubMedPubMedCentralGoogle Scholar
  43. 43.
    Fleming T, Dunne J, Crowley B. Ex vivo monitoring of human cytomegalovirus-specific CD8(+) T-cell responses using the QuantiFERON-CMV assay in allogeneic hematopoietic stem cell transplant recipients attending an Irish hospital. J Med Virol. 2010;82(3):433–40.CrossRefGoogle Scholar
  44. 44.
    Camargo JF, Wieder ED, Kimble E, et al. Deep functional immunophenotyping predicts risk of cytomegalovirus reactivation after hematopoietic cell transplantation. Blood. 2019;133(8):867–77.CrossRefGoogle Scholar
  45. 45.
    Sylwester AW, Mitchell BL, Edgar JB, et al. Broadly targeted human cytomegalovirus-specific CD4+ and CD8+ T cells dominate the memory compartments of exposed subjects. J Exp Med. 2005;202(5):673–85.CrossRefPubMedPubMedCentralGoogle Scholar
  46. 46.
    Suarez JF, Rosa R, Lorio MA, et al. Pretransplant CD4 count influences immune reconstitution and risk of infectious complications in human immunodeficiency virus-infected kidney allograft recipients. Am J Transplant. 2016;16(8):2463–72.CrossRefPubMedPubMedCentralGoogle Scholar
  47. 47.
    Heining C, Spyridonidis A, Bernhardt E, et al. Lymphocyte reconstitution following allogeneic hematopoietic stem cell transplantation: a retrospective study including 148 patients. Bone Marrow Transplant. 2007;39(10):613–22.CrossRefGoogle Scholar
  48. 48.
    Betts MR, Nason MC, West SM, et al. HIV nonprogressors preferentially maintain highly functional HIV-specific CD8+ T cells. Blood. 2006;107(12):4781–9.CrossRefPubMedPubMedCentralGoogle Scholar
  49. 49.
    Lilleri D, Fornara C, Chiesa A, Caldera D, Alessandrino EP, Gerna G. Human cytomegalovirus-specific CD4+ and CD8+ T-cell reconstitution in adult allogeneic hematopoietic stem cell transplant recipients and immune control of viral infection. Haematologica. 2008;93(2):248–56.CrossRefGoogle Scholar
  50. 50.
    Pelak O, Stuchly J, Krol L, et al. Appearance of cytomegalovirus-specific T-cells predicts fast resolution of viremia post hematopoietic stem cell transplantation. Cytometry B Clin Cytom. 2017;92(5):380–8.CrossRefGoogle Scholar
  51. 51.
    Ljungman P, Boeckh M, Hirsch HH, et al. Definitions of cytomegalovirus infection and disease in transplant patients for use in clinical trials. Clin Infect Dis. 2017;64(1):87–91.CrossRefGoogle Scholar
  52. 52.
    Ariza-Heredia EJ, Nesher L, Chemaly RF. Cytomegalovirus diseases after hematopoietic stem cell transplantation: a mini-review. Cancer Lett. 2014;342(1):1–8.CrossRefGoogle Scholar
  53. 53.
    Erard V, Guthrie KA, Seo S, et al. Reduced mortality of cytomegalovirus pneumonia after hematopoietic cell transplantation due to antiviral therapy and changes in transplantation practices. Clin Infect Dis. 2015;61(1):31–9.CrossRefPubMedPubMedCentralGoogle Scholar
  54. 54.
    Torres HA, Aguilera E, Safdar A, et al. Fatal cytomegalovirus pneumonia in patients with haematological malignancies: an autopsy-based case-control study. Clin Microbiol Infect. 2008;14(12):1160–6.CrossRefGoogle Scholar
  55. 55.
    van Burik JA, Lawatsch EJ, DeFor TE, Weisdorf DJ. Cytomegalovirus enteritis among hematopoietic stem cell transplant recipients. Biol Blood Marrow Transplant. 2001;7(12):674–9.CrossRefGoogle Scholar
  56. 56.
    Wolf DG, Lurain NS, Zuckerman T, et al. Emergence of late cytomegalovirus central nervous system disease in hematopoietic stem cell transplant recipients. Blood. 2003;101(2):463–5.CrossRefGoogle Scholar
  57. 57.
    Jeong TD, Sung H, Choi SH, et al. Cytomegalovirus ventriculoencephalitis with compartmentalization of antiviral-resistant cytomegalovirus in a T cell-depleted haploidentical peripheral blood stem cell transplant recipient. Diagn Microbiol Infect Dis. 2012;74(3):307–10.CrossRefGoogle Scholar
  58. 58.
    Reddy SM, Winston DJ, Territo MC, Schiller GJ. CMV central nervous system disease in stem-cell transplant recipients: an increasing complication of drug-resistant CMV infection and protracted immunodeficiency. Bone Marrow Transplant. 2010;45(6):979–84.CrossRefGoogle Scholar
  59. 59.
    Schmidt-Hieber M, Schwender J, Heinz WJ, et al. Viral encephalitis after allogeneic stem cell transplantation: a rare complication with distinct characteristics of different causative agents. Haematologica. 2011;96(1):142–9.CrossRefGoogle Scholar
  60. 60.
    Song WK, Min YH, Kim YR, Lee SC. Cytomegalovirus retinitis after hematopoietic stem cell transplantation with alemtuzumab. Ophthalmology. 2008;115(10):1766–70.CrossRefPubMedPubMedCentralGoogle Scholar
  61. 61.
    Marr KA, Carter RA, Boeckh M, Martin P, Corey L. Invasive aspergillosis in allogeneic stem cell transplant recipients: changes in epidemiology and risk factors. Blood. 2002;100(13):4358–66.CrossRefPubMedPubMedCentralGoogle Scholar
  62. 62.
    Nichols WG, Corey L, Gooley T, Davis C, Boeckh M. High risk of death due to bacterial and fungal infection among cytomegalovirus (CMV)-seronegative recipients of stem cell transplants from seropositive donors: evidence for indirect effects of primary CMV infection. J Infect Dis. 2002;185(3):273–82.CrossRefPubMedPubMedCentralGoogle Scholar
  63. 63.
    Cantoni N, Hirsch HH, Khanna N, et al. Evidence for a bidirectional relationship between cytomegalovirus replication and acute graft-versus-host disease. Biol Blood Marrow Transplant. 2010;16(9):1309–14.CrossRefGoogle Scholar
  64. 64.
    Broers AE, van Der Holt R, van Esser JW, et al. Increased transplant-related morbidity and mortality in CMV-seropositive patients despite highly effective prevention of CMV disease after allogeneic T-cell-depleted stem cell transplantation. Blood. 2000;95(7):2240–5.CrossRefGoogle Scholar
  65. 65.
    Mariotti J, Maura F, Spina F, et al. Impact of cytomegalovirus replication and cytomegalovirus serostatus on the outcome of patients with B cell lymphoma after allogeneic stem cell transplantation. Biol Blood Marrow Transplant. 2014;20(6):885–90.CrossRefGoogle Scholar
  66. 66.
    Green ML, Leisenring WM, Xie H, et al. CMV reactivation after allogeneic HCT and relapse risk: evidence for early protection in acute myeloid leukemia. Blood. 2013;122(7):1316–24.CrossRefPubMedPubMedCentralGoogle Scholar
  67. 67.
    Teira P, Battiwalla M, Ramanathan M, et al. Early cytomegalovirus reactivation remains associated with increased transplant-related mortality in the current era: a CIBMTR analysis. Blood. 2016;127(20):2427–38.CrossRefPubMedPubMedCentralGoogle Scholar
  68. 68.
    Garcia-Vidal C, Upton A, Kirby KA, Marr KA. Epidemiology of invasive mold infections in allogeneic stem cell transplant recipients: biological risk factors for infection according to time after transplantation. Clin Infect Dis. 2008;47(8):1041–50.CrossRefPubMedPubMedCentralGoogle Scholar
  69. 69.
    Thursky K, Byrnes G, Grigg A, Szer J, Slavin M. Risk factors for post-engraftment invasive aspergillosis in allogeneic stem cell transplantation. Bone Marrow Transplant. 2004;34(2):115–21.CrossRefGoogle Scholar
  70. 70.
    Marr KA, Seidel K, White TC, Bowden RA. Candidemia in allogeneic blood and marrow transplant recipients: evolution of risk factors after the adoption of prophylactic fluconazole. J Infect Dis. 2000;181(1):309–16.CrossRefPubMedPubMedCentralGoogle Scholar
  71. 71.
    Venton G, Crocchiolo R, Furst S, et al. Risk factors of ganciclovir-related neutropenia after allogeneic stem cell transplantation: a retrospective monocentre study on 547 patients. Clin Microbiol Infect. 2014;20(2):160–6.CrossRefPubMedPubMedCentralGoogle Scholar
  72. 72.
    Liu J, Kong J, Chang YJ, et al. Patients with refractory cytomegalovirus (CMV) infection following allogeneic haematopoietic stem cell transplantation are at high risk for CMV disease and non-relapse mortality. Clin Microbiol Infect. 2015;21(12):1121 e9–15.CrossRefGoogle Scholar
  73. 73.
    Baniak N, Kanthan R. Cytomegalovirus colitis: an uncommon mimicker of common colitides. Arch Pathol Lab Med. 2016;140(8):854–8.CrossRefPubMedPubMedCentralGoogle Scholar
  74. 74.
    Goodman AL, Murray CD, Watkins J, Griffiths PD, Webster DP. CMV in the gut: a critical review of CMV detection in the immunocompetent host with colitis. Eur J Clin Microbiol Infect Dis. 2015;34(1):13–8.CrossRefPubMedPubMedCentralGoogle Scholar
  75. 75.
    Garrido E, Carrera E, Manzano R, Lopez-Sanroman A. Clinical significance of cytomegalovirus infection in patients with inflammatory bowel disease. World J Gastroenterol. 2013;19(1):17–25.CrossRefPubMedPubMedCentralGoogle Scholar
  76. 76.
    Cardenoso L, Pinsky BA, Lautenschlager I, et al. CMV antigenemia and quantitative viral load assessments in hematopoietic stem cell transplant recipients. J Clin Virol. 2013;56(2):108–12.CrossRefPubMedPubMedCentralGoogle Scholar
  77. 77.
    Boeckh M, Huang M, Ferrenberg J, et al. Optimization of quantitative detection of cytomegalovirus DNA in plasma by real-time PCR. J Clin Microbiol. 2004;42(3):1142–8.CrossRefPubMedPubMedCentralGoogle Scholar
  78. 78.
    Limaye AP, Huang ML, Leisenring W, Stensland L, Corey L, Boeckh M. Cytomegalovirus (CMV) DNA load in plasma for the diagnosis of CMV disease before engraftment in hematopoietic stem-cell transplant recipients. J Infect Dis. 2001;183(3):377–82.CrossRefPubMedPubMedCentralGoogle Scholar
  79. 79.
    Babady NE, Cheng C, Cumberbatch E, Stiles J, Papanicolaou G, Tang YW. Monitoring of cytomegalovirus viral loads by two molecular assays in whole-blood and plasma samples from hematopoietic stem cell transplant recipients. J Clin Microbiol. 2015;53(4):1252–7.CrossRefPubMedPubMedCentralGoogle Scholar
  80. 80.
    Kraft CS, Armstrong WS, Caliendo AM. Interpreting quantitative cytomegalovirus DNA testing: understanding the laboratory perspective. Clin Infect Dis. 2012;54(12):1793–7.CrossRefPubMedPubMedCentralGoogle Scholar
  81. 81.
    Preiksaitis JK, Hayden RT, Tong Y, et al. Are we there yet? Impact of the first international standard for cytomegalovirus DNA on the harmonization of results reported on plasma samples. Clin Infect Dis. 2016;63(5):583–9.CrossRefGoogle Scholar
  82. 82.
    Hirsch HH, Lautenschlager I, Pinsky BA, et al. An international multicenter performance analysis of cytomegalovirus load tests. Clin Infect Dis. 2013;56(3):367–73.CrossRefGoogle Scholar
  83. 83.
    Waggoner J, Ho DY, Libiran P, Pinsky BA. Clinical significance of low cytomegalovirus DNA levels in human plasma. J Clin Microbiol. 2012;50(7):2378–83.CrossRefPubMedPubMedCentralGoogle Scholar
  84. 84.
    Beam E, Germer JJ, Lahr B, et al. Cytomegalovirus (CMV) DNA quantification in bronchoalveolar lavage fluid of immunocompromised patients with CMV pneumonia. Clinical Transplantation. 2018;32:e13149: 1–8.Google Scholar
  85. 85.
    Boeckh M, Stevens-Ayers T, Travi G, et al. Cytomegalovirus (CMV) DNA quantitation in bronchoalveolar lavage fluid from hematopoietic stem cell transplant recipients with CMV pneumonia. J Infect Dis. 2017;215(10):1514–22.CrossRefPubMedPubMedCentralGoogle Scholar
  86. 86.
    Goodrich JM, Bowden RA, Fisher L, Keller C, Schoch G, Meyers JD. Ganciclovir prophylaxis to prevent cytomegalovirus disease after allogeneic marrow transplant. Ann Intern Med. 1993;118(3):173–8.CrossRefGoogle Scholar
  87. 87.
    Boeckh M, Gooley TA, Myerson D, Cunningham T, Schoch G, Bowden RA. Cytomegalovirus pp65 antigenemia-guided early treatment with ganciclovir versus ganciclovir at engraftment after allogeneic marrow transplantation: a randomized double-blind study. Blood. 1996;88(10):4063–71.CrossRefGoogle Scholar
  88. 88.
    Green ML, Leisenring W, Stachel D, et al. Efficacy of a viral load-based, risk-adapted, preemptive treatment strategy for prevention of cytomegalovirus disease after hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2012;18(11):1687–99.CrossRefPubMedPubMedCentralGoogle Scholar
  89. 89.
    Gimeno C, Solano C, Latorre JC, et al. Quantification of DNA in plasma by an automated real-time PCR assay (cytomegalovirus PCR kit) for surveillance of active cytomegalovirus infection and guidance of preemptive therapy for allogeneic hematopoietic stem cell transplant recipients. J Clin Microbiol. 2008;46(10):3311–8.CrossRefPubMedPubMedCentralGoogle Scholar
  90. 90.
    Peres RM, Costa CR, Andrade PD, et al. Surveillance of active human cytomegalovirus infection in hematopoietic stem cell transplantation (HLA sibling identical donor): search for optimal cutoff value by real-time PCR. BMC Infect Dis. 2010;10:147.CrossRefPubMedPubMedCentralGoogle Scholar
  91. 91.
    Tan SK, Waggoner JJ, Pinsky BA. Cytomegalovirus load at treatment initiation is predictive of time to resolution of viremia and duration of therapy in hematopoietic cell transplant recipients. J Clin Virol. 2015;69:179–83.CrossRefPubMedPubMedCentralGoogle Scholar
  92. 92.
    Solano C, Munoz-Cobo B, Gimenez E, et al. Pre-emptive antiviral therapy for active CMV infection in adult allo-SCT patients guided by plasma CMV DNAemia quantitation using a real-time PCR assay: clinical experience at a single center. Bone Marrow Transplant. 2013;48(7):1010–2.CrossRefGoogle Scholar
  93. 93.
    Gimenez E, Munoz-Cobo B, Solano C, Amat P, Navarro D. Early kinetics of plasma cytomegalovirus DNA load in allogeneic stem cell transplant recipients in the era of highly sensitive real-time PCR assays: does it have any clinical value? J Clin Microbiol. 2014;52(2):654–6.CrossRefPubMedPubMedCentralGoogle Scholar
  94. 94.
    Emery VC, Cope AV, Bowen EF, Gor D, Griffiths PD. The dynamics of human cytomegalovirus replication in vivo. J Exp Med. 1999;190(2):177–82.CrossRefPubMedPubMedCentralGoogle Scholar
  95. 95.
    Emery VC, Sabin CA, Cope AV, Gor D, Hassan-Walker AF, Griffiths PD. Application of viral-load kinetics to identify patients who develop cytomegalovirus disease after transplantation. Lancet. 2000;355(9220):2032–6.CrossRefGoogle Scholar
  96. 96.
    Munoz-Cobo B, Solano C, Costa E, et al. Dynamics of cytomegalovirus (CMV) plasma DNAemia in initial and recurrent episodes of active CMV infection in the allogeneic stem cell transplantation setting: implications for designing preemptive antiviral therapy strategies. Biol Blood Marrow Transplant. 2011;17(11):1602–11.CrossRefGoogle Scholar
  97. 97.
    Solano C, Gimenez E, Pinana JL, et al. Preemptive antiviral therapy for CMV infection in allogeneic stem cell transplant recipients guided by the viral doubling time in the blood. Bone Marrow Transplant. 2016;51(5):718–21.CrossRefGoogle Scholar
  98. 98.
    Lodding IP, Sengelov H, da Cunha-Bang C, et al. Clinical application of variation in replication kinetics during episodes of post-transplant cytomegalovirus infections. EBioMedicine. 2015;2(7):699–705.CrossRefPubMedPubMedCentralGoogle Scholar
  99. 99.
    Solano C, Gimenez E, Pinana JL, et al. When should preemptive antiviral therapy for active CMV infection be withdrawn from allogeneic stem cell transplant recipients? Bone Marrow Transplant. 2017;52(10):1448–51.CrossRefGoogle Scholar
  100. 100.
    Manuel O, Husain S, Kumar D, et al. Assessment of cytomegalovirus-specific cell-mediated immunity for the prediction of cytomegalovirus disease in high-risk solid-organ transplant recipients: a multicenter cohort study. Clin Infect Dis. 2013;56(6):817–24.CrossRefGoogle Scholar
  101. 101.
    Clari MA, Munoz-Cobo B, Solano C, et al. Performance of the QuantiFERON-cytomegalovirus (CMV) assay for detection and estimation of the magnitude and functionality of the CMV-specific gamma interferon-producing CD8(+) T-cell response in allogeneic stem cell transplant recipients. Clin Vaccine Immunol. 2012;19(5):791–6.CrossRefPubMedPubMedCentralGoogle Scholar
  102. 102.
    Navarro D, Amat P, de la Camara R, et al. Efficacy and safety of a preemptive antiviral therapy strategy based on combined virological and immunological monitoring for active cytomegalovirus infection in allogeneic stem cell transplant recipients. Open Forum Infect Dis. 2016;3(2):ofw107.CrossRefPubMedPubMedCentralGoogle Scholar
  103. 103.
    El Haddad L, Ariza-Heredia E, Shah DP, et al. The ability of a cytomegalovirus ELISPOT assay to predict outcome of low-level CMV reactivation in hematopoietic cell transplant recipients. J Infect Dis. 2019;219(6):898–907.CrossRefGoogle Scholar
  104. 104.
    Auletta JJ. T’ing off on posttransplant CMV. Blood. 2019;133(8):777–9.CrossRefGoogle Scholar
  105. 105.
    Reusser P, Einsele H, Lee J, et al. Randomized multicenter trial of foscarnet versus ganciclovir for preemptive therapy of cytomegalovirus infection after allogeneic stem cell transplantation. Blood. 2002;99(4):1159–64.CrossRefGoogle Scholar
  106. 106.
    Camargo JF, Anderson AD, Rosa R, Kimble E, Komanduri KV, Morris MI. Use of maintenance therapy and incidence of recurrent Cytomegalovirus DNAemia among allogeneic hematopoietic cell transplant recipients. Transpl Infect Dis. 2019;21(2):e13054.CrossRefGoogle Scholar
  107. 107.
    Griffiths PD, Rothwell E, Raza M, et al. Randomized controlled trials to define viral load thresholds for cytomegalovirus pre-emptive therapy. PLoS One. 2016;11(9):e0163722.CrossRefPubMedPubMedCentralGoogle Scholar
  108. 108.
    Kumar D, Mian M, Singer L, Humar A. An interventional study using cell-mediated immunity to personalize therapy for cytomegalovirus infection after transplantation. Am J Transplant. 2017;17(9):2468–73.CrossRefGoogle Scholar
  109. 109.
    Chen K, Cheng MP, Hammond SP, Einsele H, Marty FM. Antiviral prophylaxis for cytomegalovirus infection in allogeneic hematopoietic cell transplantation. Blood Adv. 2018;2(16):2159–75.CrossRefPubMedPubMedCentralGoogle Scholar
  110. 110.
    Boeckh M, Nichols WG, Chemaly RF, et al. Valganciclovir for the prevention of complications of late cytomegalovirus infection after allogeneic hematopoietic cell transplantation: a randomized trial. Ann Intern Med. 2015;162(1):1–10.CrossRefPubMedPubMedCentralGoogle Scholar
  111. 111.
    Burns LJ, Miller W, Kandaswamy C, et al. Randomized clinical trial of ganciclovir vs acyclovir for prevention of cytomegalovirus antigenemia after allogeneic transplantation. Bone Marrow Transplant. 2002;30(12):945–51.CrossRefPubMedPubMedCentralGoogle Scholar
  112. 112.
    Kimball LE, Stevens-Ayers T, Green ML, et al. A multicenter, longitudinal, interventional, double blind randomized clinical trial in hematopoietic cell transplant recipients residing in remote areas: lessons learned from the late cytomegalovirus prevention trial. Contemp Clin Trials Commun. 2016;4:84–9.CrossRefPubMedPubMedCentralGoogle Scholar
  113. 113.
    Winston DJ, Ho WG, Bartoni K, et al. Ganciclovir prophylaxis of cytomegalovirus infection and disease in allogeneic bone marrow transplant recipients. Results of a placebo-controlled, double-blind trial. Ann Intern Med. 1993;118(3):179–84.CrossRefPubMedPubMedCentralGoogle Scholar
  114. 114.
    Nakamura R, Cortez K, Solomon S, et al. High-dose acyclovir and pre-emptive ganciclovir to prevent cytomegalovirus disease in myeloablative and non-myeloablative allogeneic stem cell transplantation. Bone Marrow Transplant. 2002;30(4):235–42.CrossRefPubMedPubMedCentralGoogle Scholar
  115. 115.
    Ljungman P, de La Camara R, Milpied N, et al. Randomized study of valacyclovir as prophylaxis against cytomegalovirus reactivation in recipients of allogeneic bone marrow transplants. Blood. 2002;99(8):3050–6.CrossRefPubMedPubMedCentralGoogle Scholar
  116. 116.
    Vusirikala M, Wolff SN, Stein RS, et al. Valacyclovir for the prevention of cytomegalovirus infection after allogeneic stem cell transplantation: a single institution retrospective cohort analysis. Bone Marrow Transplant. 2001;28(3):265–70.CrossRefPubMedPubMedCentralGoogle Scholar
  117. 117.
    Hill JA, Pergam SA, Cox E, et al. A modified intensive strategy to prevent cytomegalovirus disease in seropositive umbilical cord blood transplantation recipients. Biol Blood Marrow Transplant. 2018;24(10):2094–100.CrossRefPubMedPubMedCentralGoogle Scholar
  118. 118.
    Winston DJ, Young JA, Pullarkat V, et al. Maribavir prophylaxis for prevention of cytomegalovirus infection in allogeneic stem cell transplant recipients: a multicenter, randomized, double-blind, placebo-controlled, dose-ranging study. Blood. 2008;111(11):5403–10.CrossRefPubMedPubMedCentralGoogle Scholar
  119. 119.
    Marty FM, Ljungman P, Papanicolaou GA, et al. Maribavir prophylaxis for prevention of cytomegalovirus disease in recipients of allogeneic stem-cell transplants: a phase 3, double-blind, placebo-controlled, randomised trial. Lancet Infect Dis. 2011;11(4):284–92.CrossRefPubMedPubMedCentralGoogle Scholar
  120. 120.
    Marty FM, Boeckh M. Maribavir and human cytomegalovirus-what happened in the clinical trials and why might the drug have failed? Curr Opin Virol. 2011;1(6):555–62.CrossRefGoogle Scholar
  121. 121.
    Marty FM, Winston DJ, Rowley SD, et al. CMX001 to prevent cytomegalovirus disease in hematopoietic-cell transplantation. N Engl J Med. 2013;369(13):1227–36.CrossRefGoogle Scholar
  122. 122.
    Marty FM, Winston DJ, Chemaly RF, et al. A randomized, double-blind, placebo-controlled phase 3 trial of oral brincidofovir for cytomegalovirus prophylaxis in allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2019;25(2):369–81.CrossRefGoogle Scholar
  123. 123.
    Robin C, Thiebaut A, Alain S, de Fontbrune FS, Berceanu A, D’Aveni M, Ceballos P, Redjoul R, Nguyen-Quoc S, Bénard N, Pahlavan-Grumel G, Cordonnier C. Letermovir for secondary prophylaxis of CMV infection and disease after allogeneic hematopoietic cell transplantation: results from the French compassionate program. Biol Blood Marrow Transplant. 2020. pii: S1083-8791(20)30060-4.
  124. 124.
    Knoll BM, Seiter K, Phillips A, Soave R. Breakthrough cytomegalovirus pneumonia in hematopoietic stem cell transplant recipient on letermovir prophylaxis. Bone Marrow Transplant. 2019;54(6):911–2.CrossRefGoogle Scholar
  125. 125.
    Lischka P, Michel D, Zimmermann H. Characterization of cytomegalovirus breakthrough events in a phase 2 prophylaxis trial of letermovir (AIC246, MK 8228). J Infect Dis. 2016;213(1):23–30.CrossRefGoogle Scholar
  126. 126.
    Hill JA, Mayer BT, Xie H, et al. The cumulative burden of double-stranded DNA virus detection after allogeneic HCT is associated with increased mortality. Blood. 2017;129(16):2316–25.CrossRefPubMedPubMedCentralGoogle Scholar
  127. 127.
    Camargo JF, Morris MI, Abbo LM, et al. The use of brincidofovir for the treatment of mixed dsDNA viral infection. J Clin Virol. 2016;83:1–4.CrossRefGoogle Scholar
  128. 128.
    Marty FM, Bryar J, Browne SK, et al. Sirolimus-based graft-versus-host disease prophylaxis protects against cytomegalovirus reactivation after allogeneic hematopoietic stem cell transplantation: a cohort analysis. Blood. 2007;110(2):490–500.CrossRefPubMedPubMedCentralGoogle Scholar
  129. 129.
    Guglieri-Lopez B, Perez-Pitarch A, Garcia-Cadenas I, et al. Effect of sirolimus exposure on the need for preemptive antiviral therapy for cytomeglovirus infection after allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2019;25(5):1022–30.CrossRefGoogle Scholar
  130. 130.
    Pinana JL, Perez-Pitarch A, Guglieri-Lopez B, et al. Sirolimus exposure and the occurrence of cytomegalovirus DNAemia after allogeneic hematopoietic stem cell transplantation. Am J Transplant. 2018;18(12):2885–94.CrossRefGoogle Scholar
  131. 131.
    Raanani P, Gafter-Gvili A, Paul M, Ben-Bassat I, Leibovici L, Shpilberg O. Immunoglobulin prophylaxis in hematological malignancies and hematopoietic stem cell transplantation. Cochrane Database Syst Rev. 2008;(4):CD006501.Google Scholar
  132. 132.
    Turner N, Strand A, Grewal DS, et al. Use of letermovir as salvage therapy for drug-resistant cytomegalovirus retinitis. Antimicrob Agents Chemother. 2019 Feb 26;63(3); e02337–18: 1–6Google Scholar
  133. 133.
    Kaul DR, Stoelben S, Cober E, et al. First report of successful treatment of multidrug-resistant cytomegalovirus disease with the novel anti-CMV compound AIC246. Am J Transplant. 2011;11(5):1079–84.CrossRefGoogle Scholar
  134. 134.
    Chemaly RF, Chou S, Einsele H, et al. Definitions of resistant and refractory cytomegalovirus infection and disease in transplant recipients for use in clinical trials. Clin Infect Dis. 2019;68(8):1420–6.CrossRefGoogle Scholar
  135. 135.
    Chou SW. Cytomegalovirus drug resistance and clinical implications. Transpl Infect Dis. 2001;3(Suppl 2):20–4.CrossRefGoogle Scholar
  136. 136.
    Gilbert C, Roy J, Belanger R, et al. Lack of emergence of cytomegalovirus UL97 mutations conferring ganciclovir (GCV) resistance following preemptive GCV therapy in allogeneic stem cell transplant recipients. Antimicrob Agents Chemother. 2001;45(12):3669–71.CrossRefPubMedPubMedCentralGoogle Scholar
  137. 137.
    Hantz S, Garnier-Geoffroy F, Mazeron MC, et al. Drug-resistant cytomegalovirus in transplant recipients: a French cohort study. J Antimicrob Chemother. 2010;65(12):2628–40.CrossRefGoogle Scholar
  138. 138.
    Allice T, Busca A, Locatelli F, Falda M, Pittaluga F, Ghisetti V. Valganciclovir as pre-emptive therapy for cytomegalovirus infection post-allogenic stem cell transplantation: implications for the emergence of drug-resistant cytomegalovirus. J Antimicrob Chemother. 2009;63(3):600–8.CrossRefGoogle Scholar
  139. 139.
    Boeckh M, Nichols WG, Papanicolaou G, Rubin R, Wingard JR, Zaia J. Cytomegalovirus in hematopoietic stem cell transplant recipients: current status, known challenges, and future strategies. Biol Blood Marrow Transplant. 2003;9(9):543–58.CrossRefGoogle Scholar
  140. 140.
    Shmueli E, Or R, Shapira MY, et al. High rate of cytomegalovirus drug resistance among patients receiving preemptive antiviral treatment after haploidentical stem cell transplantation. J Infect Dis. 2014;209(4):557–61.CrossRefGoogle Scholar
  141. 141.
    Chou S, Ercolani RJ, Sahoo MK, Lefterova MI, Strasfeld LM, Pinsky BA. Improved detection of emerging drug-resistant mutant cytomegalovirus subpopulations by deep sequencing. Antimicrob Agents Chemother. 2014;58(8):4697–702.CrossRefPubMedPubMedCentralGoogle Scholar
  142. 142.
    Sahoo MK, Lefterova MI, Yamamoto F, et al. Detection of cytomegalovirus drug resistance mutations by next-generation sequencing. J Clin Microbiol. 2013;51(11):3700–10.CrossRefPubMedPubMedCentralGoogle Scholar
  143. 143.
    Chou S, Marousek GI. Maribavir antagonizes the antiviral action of ganciclovir on human cytomegalovirus. Antimicrob Agents Chemother. 2006;50(10):3470–2.CrossRefPubMedPubMedCentralGoogle Scholar
  144. 144.
    Kotton CN, Kumar D, Caliendo AM, et al. The third international consensus guidelines on the management of cytomegalovirus in solid-organ transplantation. Transplantation. 2018;102(6):900–31.CrossRefPubMedPubMedCentralGoogle Scholar
  145. 145.
    Hakki M, Chou S. The biology of cytomegalovirus drug resistance. Curr Opin Infect Dis. 2011;24(6):605–11.CrossRefPubMedPubMedCentralGoogle Scholar
  146. 146.
    Chou S. Comparison of cytomegalovirus terminase gene mutations selected after exposure to three distinct inhibitor compounds. Antimicrob Agents Chemother. 2017 Oct 24;61(11); e01325–17: 1–11.Google Scholar
  147. 147.
    Chou S. A third component of the human cytomegalovirus terminase complex is involved in letermovir resistance. Antivir Res. 2017;148:1–4.CrossRefGoogle Scholar
  148. 148.
    Chou S. Approach to drug-resistant cytomegalovirus in transplant recipients. Curr Opin Infect Dis. 2015;28(4):293–9.CrossRefPubMedPubMedCentralGoogle Scholar
  149. 149.
    Piret J, Boivin G. Clinical development of letermovir and maribavir: overview of human cytomegalovirus drug resistance. Antivir Res. 2019;163:91–105.CrossRefGoogle Scholar
  150. 150.
    Goldner T, Hempel C, Ruebsamen-Schaeff H, Zimmermann H, Lischka P. Geno- and phenotypic characterization of human cytomegalovirus mutants selected in vitro after letermovir (AIC246) exposure. Antimicrob Agents Chemother. 2014;58(1):610–3.CrossRefPubMedPubMedCentralGoogle Scholar
  151. 151.
    Cherrier L, Nasar A, Goodlet KJ, Nailor MD, Tokman S, Chou S. Emergence of letermovir resistance in a lung transplant recipient with ganciclovir-resistant cytomegalovirus infection. Am J Transplant. 2018;18(12):3060–4.CrossRefPubMedPubMedCentralGoogle Scholar
  152. 152.
    Frietsch JJ, Michel D, Stamminger T, et al. In vivo emergence of UL56 C325Y cytomegalovirus resistance to letermovir in a patient with acute myeloid leukemia after hematopoietic cell transplantation. Mediterr J Hematol Infect Dis. 2019;11(1):e2019001.CrossRefPubMedPubMedCentralGoogle Scholar
  153. 153.
    Chou S, Satterwhite LE, Ercolani RJ. New locus of drug resistance in the human cytomegalovirus UL56 gene revealed by in vitro exposure to letermovir and ganciclovir. Antimicrob Agents Chemother. 2018 Aug 27;62(9); e00922–18: 1–6Google Scholar
  154. 154.
    Tzannou I, Papadopoulou A, Naik S, et al. Off-the-shelf virus-specific T cells to treat BK virus, human herpesvirus 6, cytomegalovirus, Epstein-Barr virus, and adenovirus infections after allogeneic hematopoietic stem-cell transplantation. J Clin Oncol. 2017;35(31):3547–57.CrossRefPubMedPubMedCentralGoogle Scholar
  155. 155.
    Koehne G, Hasan A, Doubrovina E, et al. Immunotherapy with donor T cells sensitized with overlapping pentadecapeptides for treatment of persistent cytomegalovirus infection or viremia. Biol Blood Marrow Transplant. 2015;21(9):1663–78.CrossRefPubMedPubMedCentralGoogle Scholar
  156. 156.
    Gerdemann U, Katari UL, Papadopoulou A, et al. Safety and clinical efficacy of rapidly-generated trivirus-directed T cells as treatment for adenovirus, EBV, and CMV infections after allogeneic hematopoietic stem cell transplant. Mol Ther. 2013;21(11):2113–21.CrossRefPubMedPubMedCentralGoogle Scholar
  157. 157.
    Leen AM, Bollard CM, Mendizabal AM, et al. Multicenter study of banked third-party virus-specific T cells to treat severe viral infections after hematopoietic stem cell transplantation. Blood. 2013;121(26):5113–23.CrossRefPubMedPubMedCentralGoogle Scholar
  158. 158.
    Papadopoulou A, Gerdemann U, Katari UL, et al. Activity of broad-spectrum T cells as treatment for AdV, EBV, CMV, BKV, and HHV6 infections after HSCT. Sci Transl Med. 2014;6(242):242ra83.CrossRefPubMedPubMedCentralGoogle Scholar
  159. 159.
    Withers B, Blyth E, Clancy LE, et al. Long-term control of recurrent or refractory viral infections after allogeneic HSCT with third-party virus-specific T cells. Blood Adv. 2017;1(24):2193–205.CrossRefPubMedPubMedCentralGoogle Scholar
  160. 160.
    Brestrich G, Zwinger S, Fischer A, et al. Adoptive T-cell therapy of a lung transplanted patient with severe CMV disease and resistance to antiviral therapy. Am J Transplant. 2009;9(7):1679–84.CrossRefPubMedPubMedCentralGoogle Scholar
  161. 161.
    Smith C, Beagley L, Rehan S, et al. Autologous adoptive T-cell therapy for recurrent or drug-resistant cytomegalovirus complications in solid organ transplant recipients: a single-arm open-label phase I clinical trial. Clin Infect Dis. 2019;68(4):632–40.CrossRefPubMedPubMedCentralGoogle Scholar
  162. 162.
    Papanicolaou GA, Silveira FP, Langston AA, et al. Maribavir for refractory or resistant cytomegalovirus infections in hematopoietic-cell or solid-organ transplant recipients: a randomized, dose-ranging, double-blind, phase 2 study. Clin Infect Dis. 2019;68(8):1255–64.CrossRefPubMedPubMedCentralGoogle Scholar
  163. 163.
    El-Haddad D, El Chaer F, Vanichanan J, et al. Brincidofovir (CMX-001) for refractory and resistant CMV and HSV infections in immunocompromised cancer patients: a single-center experience. Antivir Res. 2016;134:58–62.CrossRefPubMedPubMedCentralGoogle Scholar
  164. 164.
    Chong PP, Teiber D, Prokesch BC, et al. Letermovir successfully used for secondary prophylaxis in a heart transplant recipient with ganciclovir-resistant cytomegalovirus syndrome (UL97 mutation). Transpl Infect Dis. 2018;20(5):e12965.CrossRefGoogle Scholar
  165. 165.
    Macesic N, Langsford D, Nicholls K, et al. Adoptive T cell immunotherapy for treatment of ganciclovir-resistant cytomegalovirus disease in a renal transplant recipient. Am J Transplant. 2015;15(3):827–32.CrossRefGoogle Scholar
  166. 166.
    Einsele H, Roosnek E, Rufer N, et al. Infusion of cytomegalovirus (CMV)-specific T cells for the treatment of CMV infection not responding to antiviral chemotherapy. Blood. 2002;99(11):3916–22.CrossRefGoogle Scholar
  167. 167.
    Blyth E, Clancy L, Simms R, et al. Donor-derived CMV-specific T cells reduce the requirement for CMV-directed pharmacotherapy after allogeneic stem cell transplantation. Blood. 2013;121(18):3745–58.CrossRefGoogle Scholar
  168. 168.
    Waldman WJ, Knight DA, Blinder L, et al. Inhibition of cytomegalovirus in vitro and in vivo by the experimental immunosuppressive agent leflunomide. Intervirology. 1999;42(5–6):412–8.CrossRefGoogle Scholar
  169. 169.
    Waldman WJ, Knight DA, Lurain NS, et al. Novel mechanism of inhibition of cytomegalovirus by the experimental immunosuppressive agent leflunomide. Transplantation. 1999;68(6):814–25.CrossRefGoogle Scholar
  170. 170.
    Avery RK, Bolwell BJ, Yen-Lieberman B, et al. Use of leflunomide in an allogeneic bone marrow transplant recipient with refractory cytomegalovirus infection. Bone Marrow Transplant. 2004;34(12):1071–5.CrossRefGoogle Scholar
  171. 171.
    Avery RK, Mossad SB, Poggio E, et al. Utility of leflunomide in the treatment of complex cytomegalovirus syndromes. Transplantation. 2010;90(4):419–26.CrossRefGoogle Scholar
  172. 172.
    Ehlert K, Groll AH, Kuehn J, Vormoor J. Treatment of refractory CMV-infection following hematopoietic stem cell transplantation with the combination of foscarnet and leflunomide. Klin Padiatr. 2006;218(3):180–4.CrossRefGoogle Scholar
  173. 173.
    Battiwalla M, Paplham P, Almyroudis NG, et al. Leflunomide failure to control recurrent cytomegalovirus infection in the setting of renal failure after allogeneic stem cell transplantation. Transpl Infect Dis. 2007;9(1):28–32.CrossRefGoogle Scholar
  174. 174.
    El Chaer F, Mori N, Shah D, et al. Adjuvant and salvage therapy with leflunomide for recalcitrant cytomegalovirus infections in hematopoietic cell transplantation recipients: a case series. Antivir Res. 2016;135:91–6.CrossRefGoogle Scholar
  175. 175.
    Efferth T, Romero MR, Wolf DG, Stamminger T, Marin JJ, Marschall M. The antiviral activities of artemisinin and artesunate. Clin Infect Dis. 2008;47(6):804–11.CrossRefGoogle Scholar
  176. 176.
    Germi R, Mariette C, Alain S, et al. Success and failure of artesunate treatment in five transplant recipients with disease caused by drug-resistant cytomegalovirus. Antivir Res. 2014;101:57–61.CrossRefGoogle Scholar
  177. 177.
    Shapira MY, Resnick IB, Chou S, et al. Artesunate as a potent antiviral agent in a patient with late drug-resistant cytomegalovirus infection after hematopoietic stem cell transplantation. Clin Infect Dis. 2008;46(9):1455–7.CrossRefGoogle Scholar
  178. 178.
    Drouot E, Piret J, Boivin G. Artesunate demonstrates in vitro synergism with several antiviral agents against human cytomegalovirus. Antivir Ther. 2016;21(6):535–9.CrossRefGoogle Scholar
  179. 179.
    Sabe N, Gonzalez-Costello J, Rama I, et al. Successful outcome of ganciclovir-resistant cytomegalovirus infection in organ transplant recipients after conversion to mTOR inhibitors. Transpl Int. 2012;25(7):e78–82.CrossRefGoogle Scholar
  180. 180.
    Peggs KS, Verfuerth S, Pizzey A, et al. Adoptive cellular therapy for early cytomegalovirus infection after allogeneic stem-cell transplantation with virus-specific T-cell lines. Lancet. 2003;362(9393):1375–7.CrossRefGoogle Scholar
  181. 181.
    Peggs KS, Thomson K, Samuel E, et al. Directly selected cytomegalovirus-reactive donor T cells confer rapid and safe systemic reconstitution of virus-specific immunity following stem cell transplantation. Clin Infect Dis. 2011;52(1):49–57.CrossRefGoogle Scholar
  182. 182.
    Hanley PJ, Melenhorst JJ, Nikiforow S, et al. CMV-specific T cells generated from naive T cells recognize atypical epitopes and may be protective in vivo. Sci Transl Med. 2015;7(285):285ra63.CrossRefPubMedPubMedCentralGoogle Scholar
  183. 183.
    La Rosa C, Longmate J, Martinez J, et al. MVA vaccine encoding CMV antigens safely induces durable expansion of CMV-specific T cells in healthy adults. Blood. 2017;129(1):114–25.CrossRefPubMedPubMedCentralGoogle Scholar
  184. 184.
    Diamond DJ, La Rosa C, Chiuppesi F, et al. A fifty-year odyssey: prospects for a cytomegalovirus vaccine in transplant and congenital infection. Expert Rev Vaccines. 2018;17(10):889–911.CrossRefPubMedPubMedCentralGoogle Scholar
  185. 185.
    Anderholm KM, Bierle CJ, Schleiss MR. Cytomegalovirus vaccines: current status and future prospects. Drugs. 2016;76(17):1625–45.CrossRefPubMedPubMedCentralGoogle Scholar
  186. 186.
    Plotkin S. The history of vaccination against cytomegalovirus. Med Microbiol Immunol. 2015;204(3):247–54.CrossRefGoogle Scholar
  187. 187.
    Kharfan-Dabaja MA, Nishihori T. Vaccine therapy for cytomegalovirus in the setting of allogeneic hematopoietic cell transplantation. Expert Rev Vaccines. 2015;14(3):341–50.CrossRefGoogle Scholar
  188. 188.
    Kharfan-Dabaja MA, Boeckh M, Wilck MB, et al. A novel therapeutic cytomegalovirus DNA vaccine in allogeneic haemopoietic stem-cell transplantation: a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Infect Dis. 2012;12(4):290–9.CrossRefGoogle Scholar
  189. 189.
    Nakamura R, La Rosa C, Longmate J, et al. Viraemia, immunogenicity, and survival outcomes of cytomegalovirus chimeric epitope vaccine supplemented with PF03512676 (CMVPepVax) in allogeneic haemopoietic stem-cell transplantation: randomised phase 1b trial. Lancet Haematol. 2016;3(2):e87–98.CrossRefGoogle Scholar
  190. 190.
    La Rosa C, Longmate J, Lacey SF, et al. Clinical evaluation of safety and immunogenicity of PADRE-cytomegalovirus (CMV) and tetanus-CMV fusion peptide vaccines with or without PF03512676 adjuvant. J Infect Dis. 2012;205(8):1294–304.CrossRefPubMedPubMedCentralGoogle Scholar
  191. 191.
    Wloch MK, Smith LR, Boutsaboualoy S, et al. Safety and immunogenicity of a bivalent cytomegalovirus DNA vaccine in healthy adult subjects. J Infect Dis. 2008;197(12):1634–42.CrossRefPubMedPubMedCentralGoogle Scholar

Authors and Affiliations

  1. 1.Division of Infectious DiseasesUniversity of Miami Miller School of MedicineMiamiUSA

Section editors and affiliations

  • Michele I. Morris
    • 1
  1. 1.Division of Infectious DiseasesUniversity of Miami Miller School of MedicineMiamiUSA

Personalised recommendations